UA108954C2 - Compounds 2- (2,4,5-substituted aniline) pyrimidine - Google Patents

Compounds 2- (2,4,5-substituted aniline) pyrimidine

Info

Publication number
UA108954C2
UA108954C2 UAA201403623A UAA201403623A UA108954C2 UA 108954 C2 UA108954 C2 UA 108954C2 UA A201403623 A UAA201403623 A UA A201403623A UA A201403623 A UAA201403623 A UA A201403623A UA 108954 C2 UA108954 C2 UA 108954C2
Authority
UA
Ukraine
Prior art keywords
compounds
salts
mutant
pyrimidine
useful
Prior art date
Application number
UAA201403623A
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA108954C2 publication Critical patent/UA108954C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Заявлений винахід стосується певних 2-(2,4,5-заміщених аніліно)піримідинових сполук та їх фармацевтично прийнятних солей, які можуть бути корисними в лікуванні або попередженні хвороби або медичного стану, опосередкованого через певні мутантні форми рецептора фактора росту епідермісу (наприклад, як-то активувальний мутант L858R, мутант делеції Ехоn19 та резистентний мутант Т790М). Такі сполуки та їх солі можуть бути корисними в лікуванні або попередженні різних раків.Винахід також стосується фармацевтичних композицій, які містять названі сполуки та їх солі, зокрема, придатних поліморфних форм цих сполук та солей, проміжної сполуки, придатної для виготовлення названих сполук, та способів лікування хвороб, опосередкованих різними відмінними формами EGFR, застосовуючи названі сполуки та їх солі.The claimed invention relates to certain 2- (2,4,5-substituted anilino) pyrimidine compounds and their pharmaceutically acceptable salts, which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutant forms of the epidermal growth factor receptor (eg, as is the L858R activation mutant, the Echon19 deletion mutant and the T790M resistant mutant). The following compounds and their salts may be useful in treating or preventing various cancers. The invention also relates to pharmaceutical compositions containing said compounds and their salts, in particular suitable polymorphic forms of these compounds and salts, an intermediate suitable for the manufacture of said compounds, and methods the treatment of diseases mediated by various different forms of EGFR, using the named compounds and their salts.

UAA201403623A 2011-07-27 2012-07-25 Compounds 2- (2,4,5-substituted aniline) pyrimidine UA108954C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27

Publications (1)

Publication Number Publication Date
UA108954C2 true UA108954C2 (en) 2015-06-25

Family

ID=53675818

Family Applications (3)

Application Number Title Priority Date Filing Date
UAA201312949A UA106710C2 (en) 2011-07-27 2012-07-25 COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT
UAA201403622A UA109736C2 (en) 2011-07-27 2012-07-25 POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)
UAA201403623A UA108954C2 (en) 2011-07-27 2012-07-25 Compounds 2- (2,4,5-substituted aniline) pyrimidine

Family Applications Before (2)

Application Number Title Priority Date Filing Date
UAA201312949A UA106710C2 (en) 2011-07-27 2012-07-25 COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT
UAA201403622A UA109736C2 (en) 2011-07-27 2012-07-25 POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)

Country Status (2)

Country Link
AR (1) AR115019A2 (en)
UA (3) UA106710C2 (en)

Also Published As

Publication number Publication date
UA106710C2 (en) 2014-09-25
UA109736C2 (en) 2015-09-25
AR115019A2 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
MX377900B (en) 2-(2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT.
EA201291220A1 (en) AMINOPYRIMIDINE DERIVATIVES AS MODULATORS LRRK2
MX351305B (en) Mineralocorticoid receptor antagonists.
ECSP13012611A (en) PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2
EA201590624A1 (en) CYCLIC ETHERS OF PYRAZOL-4-IL-HETEROCYCLIL-CARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
PH12012502102A1 (en) Fused bicyclic kinase inhibitors
MX349556B (en) Aminopyrimidine derivatives as lrrk2 modulators.
MX2014006027A (en) 2-phenylaminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease.
CY1118021T1 (en) AZOLI PRODUCTION
EA201370166A1 (en) CONTAINING DIRYLACETHYLENEHYDRAZIDE THYROZINKINASE INHIBITORS
MX387443B (en) HETEROARYLCARBOXAMIDE COMPOUNDS AS RIPK2 INHIBITORS
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
UA108954C2 (en) Compounds 2- (2,4,5-substituted aniline) pyrimidine
EA202092034A3 (en) 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
NZ621471A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease